Myocardial infarction - thrombolysis
The clinical effectiveness and cost effectiveness of drugs for early thrombolysis in the treatment of acute myocardial infarction
| Guidance type: Technology appraisal |
| Date issued: October 2002 |
We will consult on our review plans for this guidance in October 2005. |
| Reference: TA52 |
SummaryThis guidance from NICE makes recommendations about which thrombolytic drugs should be used for patients who have had a heart attack. For treatment with thrombolytic drugs in hospital, NICE recommends that doctors should take the following factors into account when deciding which thrombolytic drug (alteplase, reteplase, streptokinase or tenecteplase) to use for an individual patient.
NICE has also made recommendations about which drugs to use where emergency care arrangements for people having a heart attack include giving thrombolytic drugs before the patient reaches hospital – for example, this might be the setup for communities a long way from a hospital with emergency facilities. Because of the difficulties of setting up an intravenous infusion of a thrombolytic drug somewhere other than in hospital, NICE recommends that in these circumstances a thrombolytic drug given by intravenous injection (reteplase or tenecteplase) should be used. In January 2006, following consultation, the Institute decided to make this guidance 'static.' This means that the guidance remains in force and has no scheduled review date. See the review decision below for further details |
| Top |
DocumentsFor healthcare professionals
For patients, carers and the publicBackground information |
Implementing this guidanceAny further information NICE has produced to help the NHS implement this guideline locally is linked to below:
|
| Top |
